

Tumor-Infiltrating Lymphocytes (TILs) in a Cohort of Women with DCIS

Farbod Darvishian MD¹, Sylvia Adams MD², Ugur Ozerdem MD¹, Jennifer Chun MPH³, Elizabeth Pirraglia MS⁴, Elianna Kaplowitz MPH³, Andrea Troxel ScD⁴, Alison Price MD³, Freya Schnabel MD³, Daniel Roses MD³

BACKGROUND and **PURPOSE**

- A major issue in defining ductal carcinoma in situ (DCIS) is whether it is a precursor or a risk factor for the development of invasive breast cancer.
- 50% of DCIS recurs as invasive carcinoma, which is associated with an 18.1 greater likelihood of dying from breast cancer.
- The purpose of this study was to investigate the tumor's immune microenvironment and to investigate the association of TILs in those patients who had DCIS and had a recurrence compared to those who did not recur.

METHODS

- Our institutional database was queried for all patients with pure DCIS from 2010 to 2018.
- TILs were evaluated by the guidelines published by the International Immuno-Oncology Biomarker Working-Group for evaluating TILs in DCIS (Hendry et al. Adv Anat Pathol (2017) 24(5):235–51).
- Percentage of TILs was assessed from the densest focus (hotspot) in one high power field of stroma touching the basement membrane.
- Statistical methods included cluster analyses to define sparse TILs (<45%) vs. dense TILs $(\geq 45\%)$, multivariate logistic regression to compare the clinicopathologic characteristics with TILs and the Kaplan-Meier and Cox regression models were performed to analyze disease-free survival.

1. Department of Pathology, NYU Langone Health, Perlmutter Cancer Center 2. Department of Medicine, NYU Langone Health, Perlmutter Cancer Center 3. Department of Surgery, NYU Langone Health, Perlmutter Cancer Center 4. Department of Population Health, Division of Biostatistics, NYU Langone Health

	RE	ESULTS		
Table. Clinicopathologic Factors and TILs Multivariate Analysis				
Variable	Total N=69	Sparse TILs (highest %<45) N=47	Dense TILs (highest %≥45) N=22	p-value
Median Age (years)	62.0 (34-88)	65.0 (34-88)	54.5 (35-86)	0.019
Race Black Asian Hispanic White Other	6 (9%) 8 (12%) 3 (4%) 51 (74%) 1 (1%)	4 (9%) 3 (6%) 3 (6%) 37 (79%) 0 (0%)	2 (9%) 5 (23%) 0 (0%) 14 (64%) 1 (5%)	0.502
Tumor Size (cm)	12.0 (0.1-8.0)	1.31 (0.1-5.0)	3.38 (0.8-8.0)	<0.001
Multifocal Yes No	22 (32%) 47 (68%)	15 (32%) 32 (68%)	7 (32%) 15 (68%)	0.854
Nuclear Grade Low Intermediate High	4 (6%) 26 (38%) 39 (56%)	4 (9%) 24 (51%) 19 (40%)	0 (0%) 2 (9%) 20 (91%)	0.010
Comedo Histology Yes No	21 (30%) 48 (70%)	10 (21%) 37 (79%)	11 (50%) 11 (50%)	0.033
Necrosis Yes No	48 (70%) 21 (30%)	29 (62%) 18 (38%)	19 (86%) 3 (14%)	0.027
Estrogen Receptor Positive Negative	56 (81%) 13 (19%)	41 (87%) 6 (13%)	15 (68%) 7 (32%)	0.037
Progesterone Receptor Positive Negative	52 (75%) 17 (25%)	38 (81%) 9 (19%)	14 (64%) 8 (36%)	0.081
Hormone Therapy Yes No	22 (32%) 47 (68%)	18 (38%) 29 (62%)	4 (18%) 18 (82%)	0.083
Radiation Therapy Yes No	41 (59%) 28 (41%)	26 (55%) 21 (45%)	15 (68%) 7 (32%)	0.219
Ipsilateral Recurrence Yes No	13 (19%) 56 (81%)	4 (9%) 43 (91%)	9 (41%) 13 (59%)	0.008





Figure 2. Disease Free Survival Analysis of TILs



- surgery.
- patients.





ID: 582075

RESULTS

• There were 581 (21%) patients with pure DCIS. Of those, sixty-nine patients with pure DCIS were evaluated, of whom 54 (78%) were treated by breast conserving surgery.

Out of the 69 patients evaluated for TILs, 47 (68%) had sparse TILs and 22 (32%) had dense TILs (Table and Figure 1).

The median age was 60.2 years and the median follow-up for this cohort was 6.7 years.

• After adjusting for age, dense TILs was associated with younger age (p=0.019), larger tumor size (p< 0.001), high nuclear grade (p=0.010), comedo histology (p=0.033), necrosis (p= 0.027), ERpositivity (0.037) and recurrence (p=0.008) (Table).

• We found that dense TILs was a significant predictor of recurrence (HR=4.1, 95%CI 1.0-15.9, p=0.044) (Figure 2).

CONCLUSIONS

In our study, we found that dense TILs is a significant predictor of recurrence in patients with DCIS treated by breast conserving

Our study suggests the relevance of the immune microenvironment to further profile those DCIS lesions that may be obligate precursors of invasive breast cancer.

Further studies are warranted to define the impact of immunologic and molecular profiling for the clinical management of DCIS